Abstract P atients with diabetes mellitus who present with acute ST-segment elevation myocardial infarction or non-ST-segment elevation acute coronary syndromes have a higher risk of adverse outcomes than patients without diabetes, and appear to derive greater benefit from evidence-based therapies. However, patients with diabetes mellitus are less commonly treated with proven therapies, so renewed efforts are needed to improve the quality of care and outcomes for patients with diabetes mellitus who present with acute coronary syndromes.
Introduction
The presence of diabetes mellitus increases the risk of developing coronary artery disease (CAD) two-to four-fold. 1 Among patients with CAD, diabetes is associated with an increased risk of developing an acute coronary syndrome (ACS) and an increased risk of death after acute myocardial infarction (MI). 2 This review will focus on the clinical presentation of ACS among patients with diabetes, including non-ST-segment elevation ACS (NSTE ACS) and acute STsegment elevation myocardial infarction (STEMI), and will review the relative benefits of different therapies and interventions for these syndromes.
Pathophysiology of ACS in patients with diabetes mellitus
Diabetes mellitus is characterised by vascular endothelial dysfunction and the accelerated development of atherosclerosis. Hyperglycaemia inhibits the activity of endothelial nitric oxide synthase (eNOS), reducing the production of nitric oxide (NO) and causing impairment of endothelium-dependent vasodilation. In turn, the production of free radical species is increased, further inhibiting the action of eNOS. The production of vasoconstrictive agents (namely, endothelin-1 and angiotensin II) and the extent of activity of inflammatory lymphocytic infiltration in atherosclerotic plaques are also higher among diabetics. 3 Higher levels of cytokines and matrix metalloproteinases in diabetics lead to a decrease in the synthesis and an increase in the breakdown of collagen in the fibrous cap of the atherosclerotic plaque. 3 These factors combine to reduce the mechanical stability of the plaque's fibrous cap, leading to more frequent plaque rupture and the subsequent formation of an overlying thrombus, which leads to the clinical manifestations of ACS.
Abnormalities of platelet function also contribute to the increased risk of thrombotic events among patients with diabetes mellitus (table 1). The platelets in patients with diabetes are larger, have a greater concentration of glycoprotein IIb/IIIa surface receptors, and are prone to aggregate more aggressively when stimulated compared with the platelets of patients without diabetes. 4 In vivo studies in diabetics have demonstrated increased shear-induced platelet adhesion and aggregation, augmented synthesis of pro-aggregating thromboxanes, and a high percentage of platelets circulating while in the activated state. and signs accompanying an ACS, presumably as a consequence of underlying autonomic and sensory neuropathy. Autonomic neuropathy can impair angina recognition; atypical ischaemic symptoms, including dyspnoea, nausea, vomiting, unexplained fatigue, diaphoresis or disturbances in glycaemic control, may dominate the clinical presentation of ACS in diabetics. The frequency of silent myocardial ischaemia and infarction among patients with diabetes is high. In a cohort of patients undergoing treadmill testing, more than 60% of those with silent ischaemia had diabetes, and all had underlying autonomic nervous system abnormalities despite the absence of overt vascular complications of diabetes. 6 Additionally, diabetes is often associated with abnormalities of gastric emptying which may lead to frequent non-cardiac chest pain syndromes in certain patients.
The impaired sensation of ischaemic chest discomfort among many patients with diabetes may contribute to late presentation for medical attention in the setting of an ACS, and to subsequent delayed initiation of therapy. In the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1) trial, patients with diabetes suffering from STEMI presented, on average, about 15 minutes later for treatment than nondiabetic patients. 7 In a pooled analysis of almost 70,000 patients receiving fibrinolytic therapy, the Fibrinolytic Therapy Trialists' Group found that mortality related to STEMI was 1% higher for every hour's delay in treatment from presentation. 8 A similar decrement in benefit is seen with delays in primary percutaneous coronary intervention (PCI) for STEMI. 9 This time-dependent benefit of primary reperfusion therapy in the setting of STEMI warrants the continued education of patients with diabetes on the importance of early presentation and the potential atypical clinical manifestations of myocardial ischaemia. 10 Electrocardiographic (ECG) interpretation in diabetics presenting with suspected ACS can also be confounded by the use of oral hypoglycaemic medications, which may reduce the sensitivity of the ECG for detecting characteristic changes of myocardial ischaemia. Several animal studies suggest that sulphonylurea drugs are associated with reduced amplitude of ST segment elevation and T wave peaking during the early phases of acute myocardial ischaemia and with other non-specific re-polarisation abnormalities. 11, 12 Because of these potential confounding effects on the ECG among patients with diabetes presenting with typical or atypical chest pain symptoms, these patients deserve particularly careful evaluation in the Emergency Department.
Reperfusion therapy for acute STEMI Clinical outcomes after fibrinolysis
The results of several major fibrinolytic trials provide insight into the influence of diabetes on the clinical outcomes of patients suffering a STEMI and the relative efficacy of fibrinolysis in this population. In the GUSTO-1 trial, 30-day mortality among the 5,944 patients with diabetes was 10.5%, compared with 6.2% in patients without diabetes. 7 Mortality rates at one year were approximately 60% higher among patients with diabetes (14.5%) than in those without diabetes (8.9%). The highest mortality rate (12.5%) was among diabetics treated with insulin, as compared with 9.7% in those not receiving insulin (figure 1). The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) experience also demonstrated worse outcomes in diabetics. 13 In a pooled analysis of data from several large fibrinolytic trials, patients with diabetes receiving fibrinolytic therapy had almost twice the mortality rate at 30 days compared to non-diabetics receiving the same treatment (diabetes 13.6%; no diabetes 8.7%). 8 Despite higher mortality rates, fibrinolysis was associated with a larger absolute reduction in mortality among diabetics versus non-diabetics (37 lives saved per 1,000 patients with diabetes compared to 15 lives saved per 1,000 patients without diabetes). 8 More recent studies with new pharmacological reperfusion strategies utilising bolus fibrinolytic agents (reteplase and tenecteplase) and combinations of reduced-dose fibrinolytic agents and glycoprotein (GP) IIb/IIIa inhibitors have also evaluated the relative treatment effects in patients with diabetes. [14] [15] [16] In the GUSTO-V trial, 16% of the 16,588 patients randomised to full dose reteplase or reduced-dose reteplase plus abciximab had diabetes. Diabetics receiving abciximab and reduced-dose reteplase had a higher 30-day mortality than non-diabetics (8.2% vs. 5.0%), and had a similar modest relative reduction in 30-day mortality with combination therapy, as was seen in the overall study population. 16 
Patterns of use of fibrinolytics in patients with diabetes
Despite the greater absolute benefit with reperfusion therapy, patients with diabetes are less likely to receive fibrinolytics than patients who do not have diabetes. In the Survival and Ventricular Enlargement (SAVE) study, more than 67% of enrolled patients with STEMI did not receive fibrinolytic therapy, and the presence of diabetes was among the clinical characteristics that independently predicted the non-use of fibrinolytics (figure 2). 17 The under- 
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Additional reports of nationwide practice in France and the UK have found that eligible patients with STEMI and diabetes were significantly less likely to receive primary reperfusion therapy as compared with non-diabetics. 19, 20 Concern about higher complication rates in diabetics should not preclude the use of fibrinolytic therapy in eligible patients with diabetes and STEMI. In the GUSTO-1 trial, patients with diabetes had only a small increase in moderate bleeding complications after fibrinolysis compared with nondiabetics (13% vs. 11%), and they had no increase in the risk of major bleeding events. The risk of intracranial haemorrhage in GUSTO-1 was also similar in patients with and without diabetes (0.6% vs. 0.7%). 7 In addition, experience from GUSTO-1 suggests that concern over the risk of intra-ocular haemorrhage should not preclude the use of fibrinolytic agents in diabetic patients with STEMI. 21 
Primary percutaneous coronary intervention (PCI)
Primary percutaneous transluminal coronary angioplasty (PTCA) reduces the rates of death, re-infarction and stroke compared with fibrinolytic therapy for the treatment of STEMI. 22 This strategy has rarely been studied specifically in patients with diabetes, so data regarding procedural success and long-term outcomes are derived primarily from sub-analyses of large clinical trials. The GUSTO-IIb Primary Angioplasty Sub-Study analysed the relative benefits of pharmacological and mechanical reperfusion strategies among 1,138 patients with STEMI who were randomised to primary PTCA or accelerated t-PA. 23 Patients with diabetes (16% of the total population) had higher-risk baseline clinical characteristics and more extensive coronary disease than non-diabetics. The rate of the primary end point at 30 days (death, re-MI or disabling stroke) was more frequent among diabetics treated with primary PTCA than among non-diabetics (11.1% vs. 9.3%). However, both diabetics (OR=0.70; 95% CI 0.29-1.72) and non-diabetics (OR=0.62; 95% CI 0.41-0.96) had similarly improved outcomes at 30 days with primary PTCA compared with accelerated t-PA.
In a combined analysis of two large primary PTCA trials, GUSTO IIb and RAPPORT (Primary PTCA with glycoprotein IIb/IIIa inhibitor versus placebo), the presence of diabetes did not independently predict death or re-infarction at 30 days. 24 Similarly, the presence of diabetes mellitus did not independently predict adverse in-hospital and sixmonth outcomes in a subgroup analysis of the first Primary Angioplasty in Myocardial Infarction (PAMI) trial that compared primary angioplasty with t-PA. 25 However, Thomas et al. found a three-fold increase in the risk of long-term mortality among diabetics who participated in a trial comparing streptokinase (SK) with primary angioplasty. 26 Thus, primary angioplasty appears to provide equal benefit to diabetics and non-diabetics, and the increased risk of adverse outcomes commonly seen in patients with diabetes after STEMI may be somewhat mitigated by mechanical reperfusion strategies.
The use of stents and platelet GP IIb/IIIa inhibitors in conjunction with primary PTCA reduces the risk of recurrent ischaemia and improves clinical outcomes after STEMI. 27 Several trials utilising stents and GP IIb/IIIa inhibitors have included significant numbers of patients with diabetes. The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial randomised eligible patients with STEMI to one of four primary reperfusion strategies: PTCA alone; PTCA plus the GP IIb/IIIa inhibitor, abciximab; stenting alone; or stenting plus abciximab. 28 Among the 2,082 study participants, 16.6% had diabetes and they received a similar magnitude of benefit with stenting and abciximab compared with the overall study population (OR=0.56, 95% CI 0.32-0.97 in diabetics; OR=0.54, 95% CI 0.42-0.69 in the total population). In the ADMIRAL trial, patients with STEMI undergoing primary stenting were randomised to abciximab or placebo. Patients with diabetes had a greater absolute reduction in the rate of death, MI or urgent revascularisation at 30 days compared with the total study population (absolute risk reduction [ARR] in diabetics 13.9%; in the total population 8.0%). 29 Thus, patients with diabetes who present with STEMI may derive particular benefit from a reperfusion strategy that includes primary stenting plus GP IIb/IIIa inhibition.
Despite these encouraging results, the presence of diabetes appears to increase the risk of early complications after primary PCI. In a cohort of 104 consecutive patients undergoing primary stenting for STEMI, Silva et al. demonstrated that the only independent predictors of stent thrombosis were diabetes and tobacco use. 30 This finding may reflect the heightened platelet activation and aggregation among patients with diabetes suffering from an acute STEMI.
Early invasive management for NSTE-ACS
Patients hospitalised with unstable angina or NSTEMI (collectively known as NSTE-ACS) can be managed with an 'early conservative' strategy characterised by medical sta- bilisation, non-invasive risk stratification and coronary angiography only if recurrent ischaemia develops. Alternatively, an 'early invasive' strategy can be employed, with routine angiography and revascularisation, if needed, usually within 48 hours of admission. These two approaches have been compared in several randomised, controlled trials, but have never been studied specifically among patients with diabetes.
31,32
The Fragmin and Fast Revascularization during Instability in Coronary Artery Disease (FRISC II) study randomly assigned 2,457 patients with NSTE-ACS to an early invasive or early conservative management strategy. 31 Two-hundred and ninety-nine of the patients enrolled had diabetes (13% of total study population). The absolute benefit of the early invasive strategy was greater among diabetics than among non-diabetics (ARR in diabetics = 6.2% vs. 2.3% in non-diabetics). The superiority of the early invasive approach among diabetics was also seen in the TACTICS-TIMI 18 trial, where diabetics had a greater absolute reduction in death or MI with the early invasive strategy (ARR=7.6% vs. 3.5% for the whole study population). 32 Adjunctive medical therapy for patients with diabetes and ACS Intravenous GP IIb/IIIa inhibitors for NSTE-ACS Intravenous glycoprotein IIb/IIIa receptor inhibitors have been shown to reduce the frequency of death, MI and recurrent ischaemia when used as primary therapy for patients presenting with NSTE-ACS (eptifibatide and tirofiban) and when used as an adjunct to PCI (abciximab and eptifibatide).
33, 34 The benefits of GP IIb/IIIa inhibitors for the upstream treatment of NSTE-ACS are magnified among patients with high-risk clinical features on presentation, including ST segment deviation on the presenting ECG, positive cardiac markers and diabetes mellitus.
Theroux et al. sought to determine whether diabetics derived a particular benefit from the use of tirofiban in addition to standard antithrombotic therapy for NSTE-ACS in the Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. 35 Of the 1,570 patients enrolled in PRISM-PLUS, 362 had diabetes (23%). The rate of the primary end point (death, MI or refractory ischaemia at six months) was higher among diabetics than in non-diabetics (36.2% vs. 28.1%). The rate of death or MI at six months in patients with diabetes was significantly reduced with tirofiban (19.2% vs. 11.2%; p=0.03) and the relative treatment effect of tirofiban was greater among diabetics than non-diabetics (p=0.007 for interaction).
Further evidence of an enhanced benefit of GP IIb/IIIa inhibitors in the treatment of NSTE-ACS among diabetics has been demonstrated in two recent meta-analyses. 36, 37 Roffi et al. pooled the diabetic populations enrolled in six large-scale NSTE-ACS trials evaluating the use of these agents. 36 Among 6,458 diabetic patients, treatment with GP IIb/IIIa inhibitors was associated with a significant reduction in mortality at 30 days (OR=0.74; 95% CI 0.59 -0.92; p=0.001) (figure 3). In contrast, there was no apparent survival benefit with GP IIb/IIIa inhibitors in nondiabetics. The interaction between GP IIb/IIIa inhibitor use and diabetes was statistically significant (p=0.036). The reduction in 30-day mortality with GP IIb/IIIa inhibitors in diabetics was especially pronounced among 1,279 patients who underwent PCI during the index hospitalisation (OR=0.30; 95% CI 0.14-0.69; p=0.002).
Likewise, Boersma et al. pooled individual patient data for all participants in these six large-scale ACS trials. Patients with diabetes (22% of the population) had a higher risk of 30-day death or MI compared with non-diabetics (13.7% vs. 10.6%) and seemed to derive a greater benefit with the use of GP IIb/IIIa inhibitors. 37 These results suggest an important benefit of GP IIb/IIIa inhibitors in the diabetic population presenting with NSTE-ACS, especially in the setting of early angiography and PCI.
Oral antiplatelet therapy
Given the important platelet structural and functional abnormalities among patients with diabetes, it is not surprising that these patients derive substantial benefit from the use of aspirin (ASA) therapy for the treatment of coronary disease. Among diabetics evaluated in the Antiplatelet Trialists' Collaboration Group study, ASA lowered the com- 
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No. 38 Treatment with the thienopyridine derivatives, ticlopidine or clopidogrel (alone or in combination with ASA) may provide additional benefit in reducing ischaemic events among patients with diabetes. In the Clopidogrel versus Aspirin in Patients at Risk for Ischemic Events (CAPRIE) trial, the absolute benefit of clopidogrel over aspirin was greater in diabetics (21% of the total trial population) as compared to non-diabetics (ARR=2.1% vs. 0.5% in non-diabetics). 39 The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial randomised 12,562 patients within 24 hours of an acute coronary syndrome to clopidogrel + ASA or to placebo + ASA for 3-12 months. 40 Patients with diabetes (23% of the total study population) who received clopidogrel + ASA had higher rates of cardiovascular death, non-fatal MI or stroke when compared with non-diabetics (14.2% vs. 7.9%). The absolute and relative reduction in the rate of the composite end point was similar among patients with and without diabetes receiving combination antiplatelet therapy (diabetics ARR=2.5%; non-diabetics ARR=2.0%). More than 500 (≈ 20% of study population) patients with diabetes participated in the PCI-CURE substudy, examining the outcome among patients in the CURE trial undergoing PCI during their ACS presentation. The rate of cardiovascular death and MI was reduced in this subgroup with clopidogrel by 23% compared to those receiving placebo. 41 These results suggest that combined antiplatelet therapy with ASA and clopidogrel is appropriate for eligible patients with diabetes presenting with ACS, especially for those undergoing PCI.
Odds ratio & 95% CI

Antithrombin therapy
Antithrombin therapy with unfractionated heparin (UFH) is commonly used for patients who present with STEMI. Six trials have compared ASA + UFH to ASA alone in more than 68,000 patients (over 90% of whom received concomitant fibrinolytic therapy). The addition of heparin was associated with a small reduction in in-hospital mortality compared to ASA treatment alone (≈ 5 fewer deaths per 1,000 treated). This beneficial effect was tempered by a small increase in the rate of major bleeding (≈ 2 per 1,000 treated). 42 Among patients presenting with NSTE-ACS, modest clinical trial evidence supports the use of UFH together with ASA. Individual trials have been too small to provide unequivocal evidence, though a meta-analysis aggregating data from six small trials showed a trend for a reduced rate of death or MI with ASA + UFH compared with ASA alone. 43 Unfortunately, the use of UFH for STEMI and NSTE-ACS has not been specifically studied in patients with diabetes.
Several large clinical trials have studied low molecular weight heparin (LMWH) versus UFH in the setting of non-ST elevation ACS. 44 . 45 The Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study (ESSENCE) Group randomly assigned 3,171 patients with non-ST segment elevation ACS to the LMWH, enoxaparin or to UFH. Overall, the rates of death, MI or recurrent angina were significantly lower among patients receiving enoxaparin at 14 days (ARR 3.2%, p=0.019) and 30 days (ARR 3.5%, p=0.016). The treatment effect of enoxaparin among diabetics (22% of the total population) was consistent with that seen in the total patient cohort. 44 The Thrombolysis in Myocardial Infarction (TIMI) 11B trial demonstrated similar results with enoxaparin compared with UFH. 45 Despite the apparent efficacy of LMWH, difficulties with monitoring the level of anticoagulation during PCI have limited the use of LMWH in patients with NSTE-ACS treated with an early invasive management strategy. The results of the SYNERGY (Superior Yield of the New Strategy of Enoxaparin, Revascularization & Glycoprotein IIb/IIIa Inhibitors) and A to Z (Aggrastat to Zocor) trials should hopefully clarify the role of this class of agents among diabetic patients undergoing urgent or elective PCI.
Newer direct thrombin inhibitors act against both free and clot-bound thrombin and lack most of the qualities that limit the benefits of heparin. Several direct thrombin inhibitors (lepirudin, hirudin, bivalirudin) have been evaluated in large-scale trials of patients presenting with both STEMI and NSTE-ACS. The GUSTO-IIb investigators randomised 12,142 patients presenting with NSTE-ACS or STEMI to 72 hours of therapy with either UFH or hirudin. 46 The 30-day rate of death or MI (the primary end point) was 8.9% for those receiving hirudin and 9.8% for those receiving heparin (OR=0.89; 95% CI 0.79-1.00; p=0.06). The event rates for patients with diabetes were not reported in the published results, but the authors did not indicate the presence of an unfavourable interaction between hirudin treatment and diabetic status.
Similarly, the Organization to Assess Strategies for Ischaemic Syndromes (OASIS-2) Investigators randomised 10,141 patients with NSTE-ACS to 72 hours of treatment with UFH or hirudin. The rate of the primary end point (cardiovascular death or MI at seven days) was not significantly different in the two treatment arms (4.2% with UFH vs. 3.6% with hirudin: OR=0.84; 95% CI 0.69-1.02; p=0.078). In sub-group analyses, there was no evidence of heterogeneity in the relative benefit of hirudin among diabetics. 47 Finally, the Hirulog and Early Reperfusion or Occlusion (HERO-2) Investigators studied the effect of bivalirudin versus UFH in the setting of STEMI. 48 More than 17,000 patients were randomly assigned to a 48-hour infusion of either bivalirudin or UFH, together with the standard dose of streptokinase. The primary end point (30-day mortality) occurred in 10.8% of those receiving bivalirudin vs. 10.9% of those receiving heparin (ARR=0.1%; p=0.85). The 30-day mortality rate was substantially greater among diabetics receiving bivalirudin than in similarly treated non-diabetics (14.9% vs. 9.8%). The use of bivalirudin in diabetics was associated with a greater absolute risk reduction in death than in non-diabetics (2.7% vs. 0%). 48 As more evidence of the safety and efficacy of LMWHs in the setting of early angiography and PCI emerges, these agents will probably become the preferred antithrombin agent for patients with diabetes who present with ACS, REVIEW given the advantages outlined above. Direct thrombin inhibitors have been shown to have only modest benefit beyond UFH in the setting of STEMI and NSTE-ACS, and so will likely remain the anticoagulant of choice in the setting of heparin-induced thrombocytopenia, or when UFH or LMWH are contra-indicated. However, recent data suggest that bivalirudin provides similar benefit to GP IIb/IIIa inhibitors and unfractionated heparin when used during elective PCI, so further studies are underway to evaluate the use of bivalirudin as an upstream medical therapy for patients. 49 Beta-adrenergic antagonists Physicians have had reservations regarding the use of beta blockers in diabetic patients because of the perceived risk of masking hypoglycaemia and reducing insulin production. 3 However, most studies show equal or greater reductions in mortality and re-infarction with beta blockers in diabetics than in those without diabetes. 50, 51 Malmberg et al. conducted a retrospective review of diabetics participating in two trials randomising patients with an acute MI to metoprolol or placebo: the Göteborg Metoprolol Trial and the MIAMI Trial. 52 Among the 120 diabetics (9% of the total population) in the Göteborg trial, mortality at three months was reduced from 17.9% to 7.5% with metoprolol (p=0.16). Among the 413 patients with diabetes in the MIAMI trial, mortality was decreased by metoprolol from 11.3% to 5.7% (p=0.06). In both of these trials, the magnitude of benefit with beta blockers among diabetics was substantially greater than that among patients without diabetes.
Additional insight into the utilisation and benefits of beta blockers in diabetics after MI is found in a recent analysis of the National Cooperative Cardiovascular Project (CCP) Database. 53 Of the 45,308 Medicare beneficiaries presenting with acute MI who did not have contra-indications to beta blocker therapy, almost 26% were diabetics. Unfortunately, patients with diabetes were prescribed beta blockers on discharge after myocardial infarction in fewer than 50% of cases. After adjusting for other demographic and clinical factors, diabetics were less likely to receive beta blockers at discharge than non-diabetics (OR=0.88; 95% CI 0.82-0.96). The use of beta blockers was not associated with increased re-admission rates for diabetic complications among patients with diabetes. A similar analysis of patients in the cooperative cardiovascular project (CCP) database also demonstrated significant mortality reduction among diabetics receiving beta blockers. 54 Thus, the commonly held belief that beta blockers will increase the rate of diabetic complications and worsen glycaemic control has not been demonstrated in clinical studies, and should not preclude the use of these important agents among diabetics.
Angiotensin-converting enzyme (ACE) inhibitors
Multiple large, randomised clinical trials have unequivocally demonstrated improved survival with ACE inhibitors started during or after an acute MI. 55 Mortality and morbidity were reduced when ACE inhibitors were given during the early stages of an MI in a relatively unselected population of patients, [56] [57] [58] as well as when they were started 
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The ACE Inhibitor Myocardial Infarction Collaborative Group recently published a systematic overview of all randomised trials in which ACE inhibitors were started in the early phase of acute MI and were continued for at least 4-6 weeks. 55 In this large dataset of more than 98,000 patients, 30-day mortality was 7.1% among those treated with ACE inhibitors and 7.6% among controls, corresponding to a 7% relative reduction in mortality (p<0.004) or five deaths prevented per 1,000 patients treated. Among the 5,014 (5.1%) patients with diabetes, the absolute benefits of ACE inhibitor treatment were greater than those among non-diabetics (17.3 lives saved per 1,000 treated versus 3.2 lives saved per 1,000 treated in non-diabetics).
These results support the recommendation that diabetics suffering an acute MI should receive oral ACE inhibitor therapy early in the course of their presentation. Though not specifically studied among diabetics with NSTE-ACS, ACE inhibitors are probably beneficial in this setting, and they should be used routinely given their established benefit among patients with risk factors for or clinical manifestations of vascular disease. 62 The HOPE Investigators sought to determine whether the ACE inhibitor, ramipril reduced the risk of cardiovascular and renal disease among 3,577 diabetics participating in the overall HOPE trial (this was termed the MICRO-HOPE substudy). 62 Patients with diabetes who were included in this study had either a previous cardiovascular event or one other cardiovascular risk factor. Among these diabetics in the MICRO-HOPE substudy, ramipril reduced the rate of the composite end point of MI, stroke or death by 25%, reduced MI by 22%, stroke by 33%, and total mortality by 24% (figure 4). The rate of development of overt nephropathy was also reduced by 24% with ramipril (p=0.027). 62 Thus, the HOPE results confirm that diabetics with coronary disease derive substantial benefit from ACE inhibitors, both in the setting of an ACS and established vascular disease.
Angiotensin receptor antagonists
There are theoretical reasons why the use of angiotensin receptor antagonists (ARBs) might be beneficial when used in patients with clinical heart failure and/or left ventricular (LV) systolic dysfunction complicating the early phase of a STEMI. With ACE inhibitors, the fall in angiotensin II leads to increased renin release, which partially returns angiotensin II levels toward baseline. In addition, ACE inhibitors only block the formation of angiotensin II that is mediated by ACE. There is evidence that alternative enzymatic pathways, particularly involving chymase, exist for the production of angiotensin II within the myocardium. Several ARBs have improved clinical outcomes among patients with heart failure when added to or used in place of ACE inhibitor therapy, but these studies did not evaluate ARBs during the acute presentation for NSTE-ACS or STEMI. 63, 64 The VALIANT (Valsartan in Acute Myocardial Infarction) trial was conducted to test the hypothesis that treatment with valsartan alone or in combination with captopril would result in better survival than treatment with captopril alone in high-risk post-MI patients. Almost 15,000 patients within 10 days of a STEMI complicated by LV systolic dysfunction and/or heart failure were randomised to captopril (target dose 50 mg three times a day), valsartan (target dose 160 mg twice daily), or a combination of the two (target doses captopril 50 mg three times daily and valsartan 80 mg twice daily). After a mean follow-up of 24.7 months, there was no difference in the rate of all-cause mortality among the three treatment groups. The rates of cardiovascular death, recurrent MI and hospitalisation for heart failure were also similar among the three treatment groups. Among the 2,254 patients with diabetes enrolled in the trial, subgroup analysis did not reveal any heterogeneity in the effects of treatment on the risk of death. 65 The results of this study suggest that valsartan is as effective as an ACE inhibitor when used in high-risk patients after STEMI, but the combination of captopril + valsartan conferred no additional benefits. Thus, ARBs should only be used for patients with diabetes suffering from an acute MI who have a clear intolerance to ACE inhibitors.
Lipid-lowering therapy
The benefit of statins for secondary prevention of cardiovascular disease in patients with established coronary disease (both with and without diabetes) has been clearly demonstrated. 66 However, previous studies of statins among patients with existing vascular disease excluded patients who had experienced ACS in the 3-4 months prior to study enrolment. Given that the highest risk of death and recurrent ischaemic events occurs early after presentation with an ACS, several groups of investigators have sought to determine whether early initiation of statin therapy (prior to ACS hospital discharge) could improve outcomes and shorten time to benefit with these agents.
The Myocardial Ischemia Reduction with Aggressive Lowering (MIRACL) Study Investigators randomised more than 3,000 patients with NSTE-ACS to atorvastatin (80 mg) or placebo between 24 and 96 hours after hospital admission. The rate of the composite primary end point (death, non-fatal MI, cardiac arrest or recurrent ischaemia requiring hospitalisation) was 14.8% among those receiving atorvastatin and 17.4% among those receiving placebo (RR=0.84; 95% CI 0.70-1.00; p=0.48). The difference in event rates was entirely due to lower rates of recurrent ischaemia among those receiving atorvastatin. Though the event rates among the 23% of patients who had diabetes were not reported, there was no significant interaction between treatment assignment and the presence of diabetes. 67 A reduction in the rate of adverse cardiac events was also seen among diabetics with ACS (12% of the study population) participating in the Lescol Intervention Prevention Study (LIPS). 68 The results of the MIRACL and LIPS studies suggest that early initiation of statin therapy after presentation with ACS may reduce the rate of recurrent ischaemia requiring hospitalisation in all patients with ACS. However, the upcoming results from the Z phase of the A to Z trial will provide further information regarding the acute benefits of statins in patients with ACS. The administration of statins prior to discharge in diabetics (and all patients) presenting with an ACS may also serve to improve the likelihood that these agents will be used in the long term, where their benefits are well established.
Conclusions
Coronary artery disease is the leading cause of morbidity and mortality among patients with diabetes ( figure 5 ). Among patients with diabetes who present with ACS, the risks of adverse outcomes are much greater than those seen in patients without diabetes. 69 Healthcare providers should maintain vigilance when evaluating diabetics seeking medical care so that atypical symptoms of myocardial ischaemia are not overlooked, and should use all appropriate evidence-based therapies for patients with diabetes presenting with NSTE-ACS or STEMI since they appear to derive enhanced benefit from all proven therapies.
